Document is current

Article History

Received: 18 March 2025

Accepted: 10 August 2025

First Online: 30 October 2025

Declarations

:

: The ALFA+ study protocol has been approved by an independent Ethics Committee Parc de Salut Mar Barcelona and registered at Clinicaltrials.gov (ALFA+ Identifier: NCT02485730). The study has been conducted in accordance with the directives of the Spanish Law 14/2007, of 3rd of July, on Biomedical Research (Ley 14/2007 de Investigación Biomédica). All the participants gave written consent to participate in the study. All WRAP/ADRC participants or their caregivers provided informed written consent according to the Declaration of Helsinki. Study procedures were approved by the University of Wisconsin-Madison Institutional Review Board.

: Not applicable.

: MSC has received in the past 36mo consultancy/speaker fees (paid to the institution) from by Almirall, Eli Lilly, Novo Nordisk, and Roche Diagnostics. He has received consultancy fees or served on advisory boards (paid to the institution) of Eli Lilly, Grifols and Roche Diagnostics. He was granted a project and is a site investigator of a clinical trial (funded to the institution) by Roche Diagnostics. In-kind support for research (to the institution) was received from ADx Neurosciences, Alamar Biosciences, ALZPath, Avid Radiopharmaceuticals, Eli Lilly, Fujirebio, Janssen Research & Development, Meso Scale Discovery, and Roche Diagnostics; MSC did not receive any personal compensation from these organizations or any other for-profit organization. JDG has received research support from GE HealthCare, Roche Diagnostics, Hoffmann – La Roche and Life – MI, has participated in symposia sponsored by Biogen, Philips Nederlands, Life-MI and Esteve, acted as a consultant for Roche Diagnostics and served in the Molecular Neuroimaging Advisory Board of Prothena Biosciences. JDG is founder, co-owner and member of the Board of Directors of Betascreen SL. JDG is currently a full-time employee of AstraZeneca. SCJ has received consultancy fees or served on advisory boards for ALZPath, Enigma Biomedical, Eli Lilly and Quanterix. MTF is an employee of Syntropic Medical GmbH. In the past 3 years she has received speaking and consulting fees from Prodeco Pharma, Angelini Pharma, Roche, EPG Health unrelated to this project. MCT has received consultancy fees from Eli Lilly, Eisai and Novo nordisk. MCT has received funding from Roche. MCT is an site investigator for clinical trials with Anavex, Janssen, UCB, Novo nordisk, Passage Bio, Bristol Meyers Squibb, and Aribio.